Abstract
hNav1.7 receives a lot of attention owing to its attractive mechanism of action in pain processing pathway. We have previously reported our design of a novel series of tetrahydropyridine analogues towards hNav1.7 selective inhibitors. Herein, we disclose further efforts to the optimization of hit compound (-)-6, which led to the identification of aminocyclohexene analogues (-)-9 and (-)-17 with good potency, high selectivity, and minimal CYP inhibition. Both compounds (-)-9 and (-)-17 demonstrated improved pharmacokinetic profiles in rats, and robust efficacy in rat formalin-induced nociception and spinal nerve ligation (SNL) models.
Keywords:
Aminocyclohexene; Analgesia; Pain; Voltage-gated sodium channal; hNav1.7.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Oral
-
Analgesics / chemistry*
-
Analgesics / pharmacokinetics
-
Analgesics / therapeutic use
-
Animals
-
Binding Sites
-
Cyclohexenes / chemistry*
-
Cyclohexenes / pharmacokinetics
-
Cyclohexenes / therapeutic use
-
Cytochrome P-450 CYP2C9 / chemistry
-
Cytochrome P-450 CYP2C9 / metabolism
-
Disease Models, Animal
-
Drug Evaluation, Preclinical
-
Half-Life
-
Inhibitory Concentration 50
-
Molecular Docking Simulation
-
NAV1.7 Voltage-Gated Sodium Channel / chemistry*
-
NAV1.7 Voltage-Gated Sodium Channel / metabolism
-
Pain / drug therapy
-
Protein Structure, Tertiary
-
Rats
-
Stereoisomerism
-
Structure-Activity Relationship
-
Voltage-Gated Sodium Channel Blockers / chemistry*
-
Voltage-Gated Sodium Channel Blockers / pharmacokinetics
-
Voltage-Gated Sodium Channel Blockers / therapeutic use
Substances
-
Analgesics
-
Cyclohexenes
-
NAV1.7 Voltage-Gated Sodium Channel
-
Voltage-Gated Sodium Channel Blockers
-
cyclohexene
-
Cytochrome P-450 CYP2C9